Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lopinavir/ritonavir - Douglas pharmaceuticals

Next Previous
X
Search
Drug Profile

Lopinavir/ritonavir - Douglas pharmaceuticals

Alternative Names: DARE-CIN; DARE-HPV; DARE-HPV/CIN; R 131; R-131-2

Latest Information Update: 13 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Douglas Pharmaceuticals
  • Class Amides; Antiretrovirals; Carbamates; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cervical intraepithelial neoplasia
  • Phase I Human papillomavirus infections
  • No development reported Condylomata acuminata

Most Recent Events

  • 07 Feb 2025 Lopinavir/ritonavir is still in phase I trials for Human-papillomavirus-infections in New Zealand
  • 05 Apr 2024 Dare Bioscience has patent protection for lopinavir/ritonavir in USA
  • 05 Apr 2024 Dare Bioscience has patents pending for lopinavir/ritonavir in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top